| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT05263505 Details | 2023-11-07 Interventional | 2 | 2 | Azathioprine Methotrexate Conjunctivitis Pemphigoid, Ben… Pemphigoid, Bul… Cicatrizing Con… Mucous Membrane… | Sponsor - | |||
| NCT05111314 Details | 2023-11-07 Interventional | 1 | 0 | Edetic Acid Gallium 68 PSMA… Carcinoma Carcinoma, Hepa… Hepatocellular … | PI requested - | |||
| NCT04917055 Details | 2023-11-07 Interventional | 4 | 14 | Dexamethasone Epinephrine Ropivacaine Acute Pain Anesthesia, Loc… Knee Osteoarthr… Regional Anesth… | staffing - | |||
| NCT04631601 2020-001305-23 Details | 2023-11-07 Interventional | 1/2 | 65 | Androgen Recept… Androgens Immune Checkpoi… Prostatic Neopl… Metastatic Cast… | Amgen made a business decision to discontinue all AMG 160 clinical trials. This decision is not
related to safety. - | |||
| NCT03555149 2017-004566-99 Details | 2023-11-07 Interventional | 1/2 | 96 | Atezolizumab Bevacizumab Colorectal Neop… Colorectal Canc… | The Sponsor made the decision to terminate the study due to start up and recruitment issues
caused by limited resource availability at the treating centers. This study is not designed to make explicit power and Type I error considerations for a hypothesis test. Instead, this study is designed to obtain preliminary efficacy, safety, and PK data. No formal statistical hypothesis testing was performed in this study. Due to the limited sample size, the results need to be interpreted with caution. For the Atezo+Idasa and Atezo+LOAd703 groups, no meaningful conclusion could be drawn because these experimental arms have been terminated prematurely. | |||
| NCT02170025 2013-004595-35 Details | 2023-11-07 Interventional | 2 | [1 Refs] | 21 | Riociguat Cystic Fibrosis Fibrosis | Study was terminated after completion of Part 1, because Part 2 was no longer appropriate. Based on multiple factors, the design of part 2 is no longer appropriate. Study was terminated at the end of part 1. No safety concerns were identified. | ||
| NCT01133990 2009-016015-37 Details | 2023-11-07 Interventional | 1/2 | 5 | Bevacizumab Calcium Fluorouracil Irinotecan Leucovorin Levoleucovorin Colorectal Neop… Colorectal Canc… | The study was terminated early as the combination of E7820 and FOLFIRI was deemed to be not
tolerable, hence no efficacy analysis was conducted. The study was terminated early as the combination of E7820 and FOLFIRI was deemed to be not tolerable, hence no efficacy analysis was conducted. | |||
| NCT00668772 2007-005107-17 Details | 2023-11-07 Interventional | 3 | 207 | Salmeterol Xina… Tiotropium Brom… Pulmonary Disea… | - - | |||
| NCT05712941 Details | 2023-11-03 Interventional | 3 | 0 | Letrozole Carcinoma Endometrial Neo… Endometrial Car… | The study is being closed based on corporate changes at EQRx and is not related to any efficacy
or safety issues with lerociclib. - | |||
| NCT05405439 Details | 2023-11-03 Interventional | 1/2 | 39 | Abiraterone Ace… Prednisone Prostatic Neopl… Metastatic Cast… | The sponsor voluntarily terminated the study - | |||
| NCT04885634 2021-002017-34 Details | 2023-11-03 Interventional | 3 | 0 | Semaglutide Atrial Fibrilla… Overweight Overweight and … | Not received funding. - | |||
| NCT04397458 Details | 2023-11-03 Interventional | 4 | 0 | Bupivacaine Dexamethasone Analgesics Analgesics, Opi… Morphine Peripheral Nerv… | COVID-19 pandemic and competing study that took precedence - | |||
| NCT03605342 Details | 2023-11-03 Interventional | 2 | 37 | Buprenorphine Stress Disorder… Stress Disorder… Opiate Use Diso… Post-Traumatic … | Early termination - | |||
| NCT00625586 Details | 2023-11-03 Interventional | 2 | 2 | Gemcitabine Pancreatic Neop… Pancreatic Canc… | Corporate decision - | |||
| NCT05705492 Details | 2023-11-02 Interventional | 2 | - | Olanzapine Advanced Malign… | Pending protocol revisions - | |||
| NCT05288283 Details | 2023-11-02 Interventional | 3 | 3 | Cannabidiol Epilepsy Seizures Seizures Associ… | The study was terminated due to a business decision. - | |||
| NCT02616185 Details | 2023-11-02 Interventional | 1 | 91 | Tremelimumab Prostatic Neopl… | Due to strategic evaluation of PF-06753512 (VBIR-1) within context of Pfizer's oncology
portfolio, decision not based on any safety or regulatory concerns. The study was terminated on 20 August 2020 by the sponsor. The decision to terminate this study was based on the results of a strategic evaluation of VBIR-1 within the current Pfizer oncology portfolio. This decision was not based on any safety or regulatory concerns with the treatment of participants with VBIR-1. | |||
| NCT00687453 Details | 2023-11-02 Interventional | 4 | 27 | Insulin Glargin… Diabetes Mellit… Type 2 Diabetes… | - Early termination leading to smaller than anticipated enrollment. | |||
| NCT05546411 Details | 2023-11-01 Interventional | 2 | 8 | Camptothecin Fluorouracil Irinotecan Leucovorin Levoleucovorin Oxaliplatin Adenocarcinoma Pancreatic Neop… Borderline Rese… Pancreatic Aden… Pancreatic Canc… Resectable Panc… | Novartis, the drug manufacturer of NIS793, notified Dana Farber Cancer Institute that they are
stopping all clinical development of NIS793 in pancreatic cancer, effective immediately. - | |||
| NCT05170828 NCT05068401 Details | 2023-11-01 Interventional | 1 | 0 | Busulfan Cyclophosphamid… Fludarabine Mycophenolic Ac… Sirolimus Hematologic Neo… Leukemia Leukemia, Biphe… Myelodysplastic… Precursor Cell … Acute Biphenoty… Acute Leukemia Acute Lymphocyt… Acute Myeloid L… Acute Undiffere… T-lymphoblastic… | Change in Study Design - |